Needham Reiterates Buy on KalVista Pharma, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on KalVista Pharma (NASDAQ:KALV) and maintained a price target of $32.
September 06, 2024 | 9:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on KalVista Pharma and maintained a price target of $32, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $32 price target by a reputable analyst suggests a positive outlook for KalVista Pharma. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100